ReviewCurrent treatment options in oncology2026
The Current Cardio-Oncology Landscape Across Australia.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementCardio-oncology is a rapidly evolving subspecialty at the intersection of cancer and cardiovascular disease (CVD), two of Australia's leading causes of morbidity and mortality. Advances in cancer detection and therapy have markedly improved survival, resulting in a growing cohort of more than 1.2 million Australian cancer survivors. However, these patients are at increased risk of cardiovascular toxicity from cancer therapies, with CVD now surpassing recurrent malignancy as a leading cause of late mortality. In response, several quaternary and tertiary Australian public hospitals have established cardio-oncology services through grassroots initiatives, this has evolved into structured clinics embedded within tertiary hospitals. Despite increasing recognition and demand, access remains uneven, with services concentrated in metropolitan centres and limited provision for rural, remote, and Indigenous populations. National professional societies, including the Cardiac Society of Australia and New Zealand (CSANZ) and the Clinical Oncology Society of Australia (COSA), have recently established collaborative working groups to advance education, guidelines, and advocacy. Australia has also made significant research contributions through registries such as the Australian Cardio-Oncology Registry (ACOR) and clinical trials including SUCCOUR, BREXIT, and SMART-BREAST. Looking forward, key priorities for the Australian cardio-oncology community have surfaced including scaling workforce capacity, integrating structured education and training, expanding outreach and telehealth models, and addressing health inequities in underserved populations. These priorities along with upcoming initiatives such as the ACORES symposium will play an essential role in developing this sub speciality field. This review provides a comprehensive overview of the current cardio-oncology landscape across Australia, outlining its development, achievements, challenges, and future directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.